| 2.13 -0.08 (-3.62%) | 04-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.38 | 1-year : | 5.72 |
| Resists | First : | 3.75 | Second : | 4.9 |
| Pivot price | 2.32  |
|||
| Supports | First : | 1.9 | Second : | 1.58 |
| MAs | MA(5) : | 2.12  |
MA(20) : | 2.59 |
| MA(100) : | 5.3 |
MA(250) : | 62.5 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 18.9 |
D(3) : | 15.6 |
| RSI | RSI(14): 29.8 |
|||
| 52-week | High : | 384 | Low : | 1.9 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IVF ] has closed above bottom band by 32.6%. Bollinger Bands are 79.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 45 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.28 - 2.29 | 2.29 - 2.3 |
| Low: | 2.1 - 2.12 | 2.12 - 2.13 |
| Close: | 2.11 - 2.13 | 2.13 - 2.15 |
INVO Fertility, Inc. operates as a revenue-generating fertility business. It also focuses on the development of class clinical-stage assets in oncology and autoimmune diseases. The company was founded on January 5, 2007 and is headquartered in Sarasota, FL.
Thu, 16 Apr 2026
INVO Bioscience Inc stock (US44984F1049): Is the fertility tech edge strong enough to unlock new ups - AD HOC NEWS
Wed, 01 Apr 2026
INVO Fertility (NASDAQ: IVF) requests 15-day extension to file 2025 Form 10-K - Stock Titan
Tue, 31 Mar 2026
INVO Fertility Announces 1-for-5 Reverse Stock Split - TipRanks
Tue, 31 Mar 2026
INVO Fertility (NASDAQ: IVF) completes 1-for-5 reverse stock split - Stock Titan
Wed, 25 Mar 2026
INVO Fertility announces 1-for-5 reverse stock split - Investing.com
Wed, 25 Mar 2026
INVO Fertility, Inc. Announces 1-for-5 Reverse Stock Split Effective March 27, 2026 - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 345110 (%) |
| Held by Institutions | 1 (%) |
| Shares Short | 57 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -93.1 % |
| Return on Assets (ttm) | -48.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 22.6 % |
| Gross Profit (p.s.) | 0.39 |
| Sales Per Share | 0.99 |
| EBITDA (p.s.) | -1.03 |
| Qtrly Earnings Growth | 474.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -2.14 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 2.13 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 66780 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|